Biodesix, Inc. shares fall 9.84% intraday despite Q2 revenue beating estimates.

Biodesix, Inc. declined 9.84% intraday, despite reporting Q2 revenue that exceeded estimates and reaffirming its earnings guidance for the year. The company also announced a partnership with the Association of Pulmonary Advanced Practice Providers to deliver medical education on biomarkers in lung nodule and lung cancer programs.